| BEDSIDE
Warfarin treatment, kidney dysfunction and outcome in acute myocardial infarction patients with a history of atrial fibrillation Recent studies suggest that warfarin increases the risk of ischemic stroke and mortality in people with end-stage renal disease and atrial fibrillation (AF). It is unknown at which degree of renal dysfunction the risk outweights the benefit. Cross-sectional study with prospective follow-up in the SWEDEHEART registry. Inclusion criteria were consecutive survivors of MI with history of AF and known serum creatinine (n=24317). Patients were classified into 5 renal disease stages according to their estimated glomerular filtration rate (eGFR). Primary outcome was a composite of death, readmission due to MI, ischemic stroke and bleeding within 1 year. Secondary outcomes were each event separately. Multivariate adjustment included age, sex, comorbidities, presentation, hospital course and discharge medication. A total of 5292 (21,7%) patients received warfarin at discharge. Warfarin treatment was significantly associated with lower risk for both the primary ) and secondary outcomes (Death, 0.67 [0.61, 0.73 Purpose: The combined long-term use of vitamin K antagonists (VKA) and antiplatelet (AP) agents in patients with atrial fibrillation (AF) is generally discouraged because it entails increased risk of bleeding in the face of uncertain efficacy benefits. Therefore we evaluated the frequency of such prescription pattern and comorbidity associations. Methods: The PREvention oF thromboembolic events -European Registry in Atrial Fibrillation (PREFER in AF) prospectively enrolled patients with AF in France, Germany, Austria, Switzerland, Italy, Spain and the United Kingdom from Jan 2012 to Jan 2013. Here, we report the patterns of combined therapy with anticoagulants and (single or dual) AP therapy in this population. Results: In 7243 patients enrolled, 4799 (66.3%) were treated with a VKA (warfarin, phenprocoumon, acenocoumarol, fluindione), 808 (11.2%) with an AP alone, and 720 (9.9%) with a VKA + AP (88.8% with ASA, 21.0% with clopidogrel, 3.1% with another AP). Compared with patients only prescribed a VKA, patients on combination treatment had similar age and body mass index, but more often had paroxysmal (28.1 vs. 23.5%) or persistent (29.7 vs. 23.5%) AF (for both, p<0.01), a significantly higher prevalence of diabetes, obesity, dyslipidaemia and chronic renal insufficiency (for all, p<0.05), and significantly more frequent coexisting coronary heart disease (CHD) (58.9 vs. 19.0%; p<0.01) or peripheral arterial disease (PAD) (10.6 vs. 3.8%; p<0.01). Accordingly they had a higher mean CHA2DS2VASc score (3.8 vs. 3.5), and a higher mean HAS-BLED score (2.8 vs. 1.9) (for both, p<0.01). Most of the combination treatments were judged by all means inappropriate according to the 2010/2012 ESC guidelines, not being given because of recent stenting or an acute coronary syndrome. Detailed analyses on the appropriateness of combination therapy will be presented.
Conclusions:
The combined use of VKA and AP therapy is common in Europe, largely explained by the coexistence of AF with CHD or PAD, and not influenced by considerations on the risks of bleeding or thromboembolism. Such prescription patterns should be the target of appropriate guideline implementation programmes.
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A synthetic small molecule antidote for anticoagulants The new oral anticoagulants (NOACs) offer significant advantages over the heparins and warfarin therapies with regards to route of administration, drug interactions and predictability of bioactivity. However, the NOACs currently lack a specific reversal agent. As such concern over serious bleeding, emergency procedures and potential overdosage is heightened. We set out to rationally design, synthesize, and characterize a synthetic small molecule anticoagulant antidote (PER977). Blood was drawn from healthy human volunteers. Plasma was immediately collected and spiked with rivaroxaban or apixaban at 1x and 2x the therapeutic Cmax. Factor Xa activity was measured before and after PER977 addition using a chromogenic anti-Xa kit (Hyphen-BioMed, France). PER977 completely reversed the anti-Xa activity of rivaroxaban and apixaban in a dose-dependent fashion ex vivo in human plasma, and no pro-coagulant effects were observed. Additionally, in a rat tail transection bleeding assay, weight-matched rats were overdosed with edoxaban (see figure) , rivaroxaban, apixaban, or dabigatran as confirmed by large increases in blood loss volume. PER977 or sham was administered and after thirty minutes, blood loss volume was quantified. PER977 significantly decreased bleeding in vivo in rats treated with NOACs, reducing it
